Navigation Links
Prostate Cancer Therapeutics Market Worth $8.0 billion by 2019

DALLAS, Nov. 19, 2013 /PRNewswire-iReach/ -- The recent approval of a number of highly effective drugs, including Zytiga and Xtandi, has provided late-stage patients with a number of options and increased survival times by a number of months. These recent approvals are anticipated to generate strong revenues during the forecast following increasing uptake by physicians as the treatment algorithm shifts towards their first-line usage over Taxotere. Additionally, a very large late-stage pipeline is anticipated to produce a number of new market entrants which are superior to existing products. Overall, this is anticipated to drive rapid market growth from $4.1 billion in 2012 to $8.0 billion by 2019 at a CAGR of 10.1%.



  • A brief introduction to prostate cancer, including the disease's pathogenesis, risk factors, diagnosis, staging and treatment algorithms for each stage.
  • In-depth analysis of drugs available for the treatment of prostate cancer, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map comparing the drugs in terms of safety and efficacy.
  • Comprehensive review of the pipeline for prostate cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, program type.
  • Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action.
  • Multi-scenario forecast data of the market to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain.
  • Discussion of the drivers and barriers for market growth.
  • Discussion of the licensing and co-development deals landscape in prostate cancer, Includes an analysis of licensing deals by stage of development, molecule type and mechanism of action. Also includes an analysis of both licensing and co-development deals by year and value and network maps of licensing and co-development deals.

Order a copy of this report at

Reasons to Buy

  • Understand the different levels of prostate cancer therapies, from early-stage prostate cacner to metastatic and castrate-resistant prostate cancer.
  • Understand the vast scope and diversity of the pipeline, including which molecule types and mechanisms of action are prominent.
  • Observe the trends in clinical trial duration and size amongst clinical Phases, between molecule types and mechanisms of action, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for prostate cancer therapeutics.
  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the prostate cancer therapeutics market.

Table of Contents

List of Tables

Table 1: Prostate Cancer Therapeutics, Prostate Cancer Risk Factors
Table 2: Prostate Cancer Therapeutics, Prostate Cancer Staging
Table 3: Prostate Cancer Therapeutics, Abbreviations
Table 4: Prostate Cancer Therapeutics, Sources for Heat Map
Table 5: Prostate Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013
Table 6: Prostate Cancer Therapeutics, Global, All Pipeline Products (Preclinical/IND Filed), 2013
Table 7: Prostate Cancer Therapeutics, Global, All Pipeline Products (Phase I), 2013
Table 8: Prostate Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013
Table 9: Prostate Cancer Therapeutics, Global, All Pipeline Products (Phase III/Pre-Registration), 2013
Table 10: Prostate Cancer Therapeutics, Global, All Pipeline Products (Undisclosed Stage of Development), 2013
Table 11: Prostate Cancer, Leading Eight Markets, Market Forecast, 2012–2019
Table 12: Prostate Cancer, US, Market Forecast, 2012–2019
Table 13: Prostate Cancer, UK, Market Forecast, 2012–2019
Table 14: Prostate Cancer, France, Market Forecast, 2012–2019
Table 15: Prostate Cancer, Germany, Market Forecast, 2012–2019
Table 16: Prostate Cancer, Italy, Market Forecast, 2012–2019
Table 17: Prostate Cancer, Spain, Market Forecast, 2012–2019
Table 18: Prostate Cancer, Japan, Market Forecast, 2012–2019
Table 19: Prostate Cancer, Canada, Market Forecast, 2012–2019

Comprehensive Table of Contents and more for the report "Prostate Cancer Therapeutics Market to 2019 – Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019" is available at .

Browse more reports on Cancer Therapeutics Industry at .

About Us:

RnR Market Research is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers. Call +1 888 391 5441 with your research requirements or email the details on This e-mail address is being protected from spambots. You need JavaScript enabled to view it and we would be happy to help you find the business intelligence that you need.

Media Contact: Priyank Tiwari, RnR Market Research, + 1 888 391 5441,

News distributed by PR Newswire iReach:

SOURCE RnR Market Research
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
2. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
3. Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
4. US HIFU to Showcase High Intensity Focused Ultrasound for the Treatment of Prostate Cancer at AUA
5. Ventana licenses Gen-Probe IP for measuring ERG protein in prostate cancer patients
6. CyberKnife® Prostate SBRT Outcomes and Quality of Life Data Presented at American Urological Association Meeting
7. Arkansas Prostate Cancer Center Earns High Honor of ACR-ASTRO Accreditation
8. Breakthrough Prostate Cancer Diagnostics
9. New Research Reveals Some Natural Supplements Effective Against Prostate Cancer
10. Prostate Cancer and Bone Health
11. New Legislation To Make USPSTF More Transparent: Prostate Cancer Roundtable Supports Reform
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  ARKRAY USA ... continues to provide evidence demonstrating the accuracy of its ... Congress on Insulin Resistance, Diabetes and Cardiovascular Disease in ... both the Company,s GLUCOCARD ® 01 meter and ... accuracy requirements. The ability to accurately measure glucose levels ...
(Date:11/25/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), a ... Executive Officer Antonius Schuh, Ph.D., is scheduled to present ... Piper Jaffray Healthcare Conference. th Annual ... Hotel in New York on ... Schuh will be available for one-on-one meetings during the ...
(Date:11/25/2015)... , Nov. 25, 2015 USP ... hazardous drug preparations (e.g. pharmacists, pharmacy technicians, nurses, ... veterinary technicians). The chapter also covers all entities ... (e.g., pharmacies, hospitals, other healthcare institutions, patient treatment ... --> --> What ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, ... friendships, and learning in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, ... , For 65 years, Brillianteen has been a treasured tradition for numerous families ...
(Date:11/25/2015)... ... November 25, 2015 , ... Castlewood Treatment Center for Eating ... disorders as a result of the $20,000 raised at the center’s recent ... Golf Club in Eureka, will help individuals who otherwise might not seek treatment ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely ... resulting in a way for homeless people to have a more dignified and ... new initiative whereby they are repurposing plastic bags into sleeping mats for the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Dr. Todd S. ... offer laser services to many of his patients. Dr. Afferica now uses the BIOLASE ... reduce the amount of time the doctor uses other traditional cutting tools, such as ...
Breaking Medicine News(10 mins):